References
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021;14:103–121.
- Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370–3373. Available from: http://ashpublications.org/blood/article-pdf/106/10/3370/1636628/zh802205003370.pdf.
- Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood. 2011;118:3445–3446. Available from: http://ashpublications.org/blood/article-pdf/118/12/3445/1340381/zh803811003445.pdf.
- Ismail SI, Naffa RG, Yousef AMF, et al. Incidence of bcr–abl fusion transcripts in healthy individuals. Mol Med Rep. 2014;9:1271–1276. Available from: https://pubmed.ncbi.nlm.nih.gov/24535287/.
- Sano S, Walsh K. Hematopoietic JAK2V617F-mediated clonal hematopoiesis: AIM2 understand mechanisms of atherogenesis. J Cardiovasc Aging. 2021;1:5–8.
- Sharf G, Marin C, Bradley JA, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102–2112. Available from: https://www.nature.com/articles/s41375-020-0867-0.
- Cumbo C, Tota G, de Grassi A, et al. RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia. Leuk Lymphoma. 2021 May 24:1–5. doi:10.1080/10428194.2021.1929960.
- Langabeer SE. CALR-mutated myeloproliferative neoplasm. EXCLI J. 2020;19:86–88. doi:10.17179/excli2019-2063.
- Lorenzo M, Grille S, Stevenazzi M. Emergence of BCR-ABL1 chronic myeloid leukemia in a JAK2-V617F polycythemia vera. J Hematol. 2020;9:23–29.
- Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21:1824–1826. Available from: https://pubmed.ncbi.nlm.nih.gov/17476275/.
- Ali EAH, Al-Akiki S, Yassin MA. A case report of BCR-ABL-JAK2-positive chronic myeloid leukemia with complete hematological and major molecular response to dasatinib. Case Rep Oncol. 2021;14:690–694. Available from: https://www.karger.com/Article/FullText/514632.
- Williams N, Lee J, Mitchell E, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602:162–168.
- McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10:1239–1245.
- Fava C, Cambrin GR, Ferrero D, et al. Coexistence of a JAK2 mutated clone may cause hematologic resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009;9:E41.
- Frikha R, Turki F, Kassar O, et al. Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation? J Oncol Pharm Pract. 2021;27:1784–1789. doi:10.1177/1078155221991646?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed.
- Heyde A, Rohde D, McAlpine CS, et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell. 2021;184:1348–1361. e22.
- Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660–2672. Available from: https://pubmed.ncbi.nlm.nih.gov/32518416/.